NUVB · Nuvation Bio Inc.
$6.96
-0.14 (-1.97%)
At close · Aug 26
Market Cap
$2.47B
Shares
351.12M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.96
Open$7.09
Day$6.91–7.12
52W close$2.92–9.54
Avg vol 30d6.0M
Short int53.2M · 15.2% float · 8.9d
Short vol66%
Last earningsAug 6, 2026
DataAug 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Very Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+18%
above
Price vs 50-day avg
+12%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
61%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+52%
trailing
YTD return
−22%
this year
Relative strength
+40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +38 funds added
Insider flow
Accumulating
Net +$118.3K over 90 days · 0% sells
Short interest
Falling
15.16% of float · ▼ -0.4% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
241 holders — near 3-yr high, broad support
Squeeze score
83
high risk · 0–100
Fundamentals
Revenue growth
+699%
Y/Y
Gross margin
1%
expanding
EPS growth
+72%
Y/Y
Balance sheet
$111.2M
net cash
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+18%
Bullish
Price vs 50-day avg
+12%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
61%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
No cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +38 funds added
Insider flow
Accumulating
Net +$118.3K over 90 days · 0% sells
Short interest
Falling
15.16% of float · ▼ -0.4% MoM · 8.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
241 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $7 · 61%
Range high $10
vs 200-day avg +18%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| approximately 160 new patient starts | 160 | Q2 2026 | — |
| new patients started treatment with IBTROZI | 200 | first quarter of 2026 | — |
| new patients started treatment on IBTROZI | 216 | fourth quarter | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NUVB
this stock
Nuvation Bio Inc.
|
$2.47B | -22.3% | +699.0% | — | 15.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NUVB | -4.1% | +5.6% | +52.3% | +10.0% | -22.3% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -3.7% | +0.6% | +39.9% | +7.4% | -34.7% |
Key facts
CIK
1811063
CUSIP
67080N101
13F (30d)
212 filings
210 filers
Visit website
Investor relations